Volex (AIM: VLX) upgrades FY2026 revenue to at least $1.22bn as AI data centre demand doubles and board eyes Main Market move
Can inhaled nintedanib improve tolerability and adherence in IPF treatment, according to Avalyn Pharma Inc.?
Read More 2 minute read Pharma Industry News UCB signs $2bn worth deal with Roche for AD drug candidate UCB0107 Belgian pharma company UCB has signed a global exclusive license deal worth up to $2 billion for its… bypharmanewsdailyJuly 29, 2020
